Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Clara Dougherty

Physician Assistant, Medical La Jolla, CA Physician Assistant

NPI 1609987619 CMS profile 27849

9850 Genesee Ave, Suite 400, La Jolla, CA 92037

Open in the dashboard

General payments

$4,378

167 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Clara Dougherty of La Jolla, CA is reported in the CMS Open Payments database as having received $4,378 across 167 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 87th percentile of Physician Assistant, Medical profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,181 42
2024 General $485 19
2023 General $1,009 32
2022 General $1,052 42
2021 General $651 32

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Clara Dougherty
  • Physician Assistant, Medical median
  • Middle half of Physician Assistant, Medical
  • National median

In program year 2025, general payments to Clara Dougherty were reported at $1,181. Among 16,675 Physician Assistant, Medical profiles paid that year, the median was $214 and the middle half received between $62 and $755.

Show as a table
Year Clara Dougherty Physician Assistant, Medical median Middle half National median
2019 $0 $61 $19–$193 $163
2020 $0 $20 $14–$64 $114
2021 $651 $156 $41–$563 $132
2022 $1,052 $185 $55–$649 $149
2023 $1,009 $199 $58–$717 $160
2024 $485 $206 $62–$740 $164
2025 $1,181 $214 $62–$755 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Janssen Biotech, Inc. $687 14 payments
  2. AbbVie, Inc. $538 23 payments
  3. Teleflex LLC $483 5 payments
  4. Coloplast Corp $453 27 payments
  5. Urogen Pharma, Inc. $242 9 payments
  6. Medtronic, Inc. $236 7 payments
  7. Sumitomo Pharma America, Inc. $223 10 payments
  8. Janssen Scientific Affairs, LLC $193 3 payments
  9. Rochester Medical Corporation $171 18 payments
  10. Eisai Inc. $115 1 payment
  11. Other $1,036 50 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $4,378 167 payments
Products named General payments · program years 2021–2025
  1. ERLEADA $880 17 payments
  2. SpeediCath $354 23 payments
  3. UroLift System $296 2 payments
  4. INTERSTIM $236 7 payments
  5. BOTOX Urology $216 9 payments
  6. ZUSDURI $176 5 payments
  7. GEMTESA $174 8 payments
  8. LUPRON DEPOT $160 7 payments
  9. XTANDI $140 7 payments
  10. BOTOX Botox Therapeutic $134 6 payments
  11. Other $1,943 76 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 12 drugs

Part D claims

351

Median for Physician Assistant: 241

Drug cost

$40,548

Median for Physician Assistant: $4,110

Branded share of claims

39.9%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Gemtesa Vibegron Brand 49 $33,486
Estradiol Generic 33 $2,684
Methenamine Hippurate Generic 13 $1,138
Tamsulosin Hcl Generic 85 $898
Nitrofurantoin Nitrofurantoin Macrocrystal Brand 20 $479
Solifenacin Succinate Generic 15 $401
Cefuroxime Cefuroxime Axetil Brand 35 $397
Nitrofurantoin Mono-Macro Nitrofurantoin Monohyd/M-Cryst Brand 36 $356
Finasteride Generic 18 $302
Cephalexin Generic 17 $263

The 10 drugs with the highest cost, of 12 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 36 billing codes

Paid by Medicare

$98,139

Of which drugs: $4,002

Medicare patients

286

Average age 76

Services billed

5,029

119 women, 167 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 69%
Arthritis 52%
Ischemic heart disease 34%
Chronic kidney disease 33%
Diabetes 23%
Atrial fibrillation 23%
Depression 21%
Heart failure 20%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Bcg live intravesical instillation, 1 mg J9030 Office 13 1,589 $3,519

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 9 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
BOTOX
  • AbbVie, Inc. $107
$107 — —
ERLEADA
  • Janssen Biotech, Inc. $80
$80 — —
GEMTESA
  • Sumitomo Pharma America, Inc. $71
$71 49 —
AKEEGA
  • Janssen Biotech, Inc. $61
$61 — —
ORGOVYX
  • Sumitomo Pharma America, Inc. $41
  • PFIZER INC. $6
$47 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 9 in the dashboard with a free account

Records

167 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant, Medical in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record